PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCefazolin
Cefazolin
Cefazolin (cefazolin) is a small molecule pharmaceutical. Cefazolin was first approved as Ancef on 1982-01-01. It is used to treat bacterial endocarditis, bacterial infections, bacterial pneumonia, bacterial skin diseases, and escherichia coli infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
urogenital diseasesD000091642
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
wounds and injuriesD014947
Trade Name
FDA
EMA
Cefazolin (discontinued: Ancef, Cefazolin, Kefzol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefazolin sodium
Tradename
Company
Number
Date
Products
CEFAZOLIN AND DEXTROSEB. Braun MedicalN-050779 RX2000-07-27
3 products, RLD, RS
CEFAZOLIN IN DEXTROSEBaxterN-207131 RX2015-08-07
3 products, RLD, RS
CEFAZOLIN SODIUMHikma PharmaceuticalsN-216109 RX2022-10-07
2 products, RLD, RS
CEFAZOLIN SODIUMHQ Specialty PharmaN-211413 RX2023-05-08
1 products, RLD, RS
Show 4 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cefazolinANDA2024-10-16
cefazolin sodiumANDA2024-09-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
urinary tract infectionsEFO_0003103D014552N39.0
bacterial infections—D001424A49
bacterial skin diseases—D017192—
escherichia coli infectionsEFO_1001318D004927B96.20
soft tissue infections—D018461—
streptococcal infectionsEFO_1001476D013290—
bacterial pneumoniaEFO_1001272D018410J15.9
staphylococcal infections—D013203A49.01
bacterial endocarditisEFO_1000830D004697—
proteus infectionsEFO_1001130D011512—
Show 2 more
Agency Specific
FDA
EMA
Expiration
Code
CEFAZOLIN SODIUM, CEFAZOLIN AND DEXTROSE, B BRAUN
2023-11-23NPP
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DB: First-generation cephalosporins
— J01DB04: Cefazolin
HCPCS
Code
Description
J0689
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg
J0690
Injection, cefazolin sodium, 500 mg
Clinical
Clinical Trials
246 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative complicationsD011183—————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—3————3
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCefazolin
INNcefazolin
Description
Cefazolin is a first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively. It has a role as an antibacterial drug. It is a cephalosporin, a member of thiadiazoles, a member of tetrazoles and a beta-lactam antibiotic allergen. It is a conjugate acid of a cefazolin(1-).
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1nnc(SCC2=C(C(=O)O)N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1
Identifiers
PDB—
CAS-ID25953-19-9
RxCUI—
ChEMBL IDCHEMBL1435
ChEBI ID474053
PubChem CID33255
DrugBankDB01327
UNII IDIHS69L0Y4T (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Cefazolin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 25,340 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,285 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use